PTK6 (BRK)
PTK6, also called breast tumour kinase, is over-expressed in most breast cancers and is one of the off-targets of dasatinib; drugs made specifically against it are still experimental. This dossier gathers the 0 products (0 approved), 0 trials, 0 pathways and 0 resistance routes in the corpus that involve it, with external identifiers so it can be joined to UniProt, ChEMBL, Open Targets and the rest of biology.
Biology
An intracellular non-receptor tyrosine kinase lacking a membrane anchor; in tumours it phosphorylates STAT3, paxillin and Sam68 and cooperates with HER2 and EGFR signalling.
- Differentiated intestinal and skin epithelium
- Most breast cancers; some colon, prostate and ovarian cancers
External identifiers
Built from HGNC, Ensembl, UniProt and ChEMBL idsProducts by modality and phase
Browse products →No product in the corpus is aimed at this target yet.
Trials
Evidence ranking →No trial in the corpus names this target or one of its products.
Resistance routes
Unaddressed routes →The resistance atlas has no route that names this target.
Pathways
Pathway-to-drug matrix →No pathway diagram carries this target as a node.
Companion diagnostics
Assay registry →No companion diagnostic in the registry measures this target.
Preclinical models
All models →No model entry for this target yet; check the cancer entries on the models page.
Open questions
All open questions →No open questions recorded for this target yet. Suggest one.
Literature
Preprints →Query for this target: (TITLE:"PTK6" OR ABSTRACT:"PTK6" OR TITLE:"BRK" OR ABSTRACT:"BRK") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about PTK6 (BRK), not a curated reading list.
Export
The dossier as machine-readable JSON: identifiers from HGNC, Ensembl, UniProt and ChEMBL, products with status, trials, pathways, hotspots, open questions and assays. The full entity record is in the open API at /api/v1/entities/ptk6.json. Licence CC BY-NC 4.0.